BIONEXUS

THE PROBLEM

39%

of deaths

worldwide

52%


of deaths in

Mexico

33% of the adult population lives with one or more of these chronic conditions:

- Obesity (16%)
- High cholesterol (35%)
 Diabetes (8%)
- Hypertension (19%)
- Nonalcoholic fatty liver disease (32%)

OUR SOLUTION



Chief Scientific Officer

PhD Biomedicine Author of 8 patents, 2 granted, 1 transferred

JUAN CARLOS MATEOS PhD Chief Operating Officer







company)





From 5 to 12

Low adherence to treatment

Serious side effects

MARKET

Antihypertensives

Merformin Statins

Lipid-lowering agents Hypoglycemic agents

ACE inhibitors and ARAII

medications a day



biofarmalab.com.mx (GMP capsule

Business managemen t office

PhD Chemistry Author of 39 patents, 20 granted, 8 transferred

(Non-GMP pilot batch manufacturing)

ϹͿΛΤΕͺ

CIATEJ

manufacturing)

INVESTMENT

Lifting Stage 1 US\$ 1,150,000

Financing the cash deficit for the growth plan for the next 18 months of operation.

Technological Development

US\$ 676,000 (59%)

Strengthening the Sales Team and Marketing Act. **US\$ 269,000** (23%)

Working Capital (OPEX)

US\$ 135,180 (12%)



In the next 18 months

MILESTONE 1

> Industrial scale-up

- > GMP preclinical studies
- > API and tablets



MILESTONE 2 >Phase | Clinical Trials Contract

Contact:

Francisco Lozano Martínez flozano@newgenesis.cl

Raúl Vázquez Cassani rvazquez@newgenesis.cl

